(AKTS) Aktis Oncology, Common stock - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.081m USD | Total Return: -9.2% in 12m
Avg Turnover: 2.92M
Qual. Beats: 0
Rev. Trend: 12.2%
Warnings
High Debt/EBITDA (8.7) with thin interest coverage (-85.6)
High Debt while negative Cash Flow
Interest Coverage Ratio -85.6 is critical
Choppy
Tailwinds
No distinct edge detected
Aktis Oncology, Inc. (AKTS) is a clinical-stage biotechnology company specializing in the development of targeted radiopharmaceuticals for solid tumor treatment. The company utilizes a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting isotopes, such as Actinium-225, directly to cancer cells while minimizing exposure to healthy tissue.
The companys pipeline is led by [225Ac]Ac-AKY-1189, currently in Phase 1b clinical trials for Nectin-4 expressing tumors, including urothelial and breast cancers. A second candidate, [225Ac]Ac-AKY-2519, targets B7-H3 expressing tumors such as prostate and lung cancer. Radiopharmaceuticals represent a growing sector in oncology, shifting the treatment paradigm from broad external radiation to precise, molecularly targeted internal delivery.
Headquartered in Boston, Aktis maintains strategic collaborations with Eli Lilly and specialized nuclear research organizations like TRIUMF Innovations to support its supply chain and development efforts. For deeper insights into these clinical milestones and valuation metrics, consider reviewing the comprehensive data available on ValueRay. This business model relies on high-affinity binding molecules to improve the therapeutic index of radioactive payloads compared to traditional small-molecule approaches.
- Clinical trial results for lead candidate AKY-1189 impact valuation and investor confidence
- Strategic collaboration milestones with Eli Lilly drive non-dilutive revenue and validation
- Supply chain reliability for Actinium-225 isotope remains critical for manufacturing and scaling
- Expansion of miniprotein platform into B7-H3 expressing tumors dictates long-term growth potential
- High research and development burn rates necessitate future capital raises or partnerships
| Net Income: -51.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 9.79 > 1.0 |
| NWC/Revenue: 3.43k% < 20% (prev 999.3%; Δ 2.43k% < -1%) |
| CFO/TA -0.11 > 3% & CFO -64.5m > Net Income -51.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 19.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.3m) vs 12m ago -64.21% < -2% |
| Gross Margin: 64.29% > 18% (prev -0.06%; Δ 6.43k% > 0.5%) |
| Asset Turnover: 3.30% > 50% (prev 8.86%; Δ -5.56% > 0%) |
| Interest Coverage Ratio: -85.63 > 6 (EBITDA TTM -57.9m / Interest Expense TTM 713k) |
| A: 0.89 (Total Current Assets 543.9m - Total Current Liabilities 27.9m) / Total Assets 576.8m |
| B: -0.30 (Retained Earnings -174.9m / Total Assets 576.8m) |
| C: -0.13 (EBIT TTM -61.1m / Avg Total Assets 456.9m) |
| D: -2.48 (Book Value of Equity -175.1m / Total Liabilities 70.7m) |
| Altman-Z'' = 1.38 = BB |
| DSRI: 0.62 (Receivables 2.20m/7.03m, Revenue 15.1m/29.9m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.21 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.50 (Revenue 15.1m / 29.9m) |
| TATA: 0.02 (NI -51.9m - CFO -64.5m) / TA 576.8m) |
| Beneish M = -3.55 (Cap -4..+1) = AAA |
As of May 24, 2026, the stock is trading at USD 20.34 with a total of 128,915 shares traded.
Over the past week, the price has changed by +4.04%,
over one month by -7.55%,
over three months by +4.68% and
over the past year by -9.20%.
Aktis Oncology, Common stock has no consensus analysts rating.
Revenue TTM = 15.1m USD
EBIT TTM = -61.1m USD
EBITDA TTM = -57.9m USD
Long Term Debt = 10.1m USD (estimated: total debt 11.6m - short term 1.43m)
Short Term Debt = 1.43m USD (from shortTermDebt, last quarter)
Debt = 11.6m USD (from shortLongTermDebtTotal, last quarter) (leases 11.5m already included)
Net Debt = -506.1m USD (calculated: Debt 11.6m - CCE 517.7m)
Enterprise Value = 574.6m USD (1.08b + Debt 11.6m - CCE 517.7m)
Interest Coverage Ratio = -85.63 (Ebit TTM -61.1m / Interest Expense TTM 713k)
EV/FCF = -10.12x (Enterprise Value 574.6m / FCF TTM -56.8m)
FCF Yield = -9.88% (FCF TTM -56.8m / Enterprise Value 574.6m)
FCF Margin = -376.9% (FCF TTM -56.8m / Revenue TTM 15.1m)
Net Margin = -344.9% (Net Income TTM -51.9m / Revenue TTM 15.1m)
Gross Margin = 64.29% ((Revenue TTM 15.1m - Cost of Revenue TTM 5.38m) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev none%)
Tobins Q-Ratio = 1.00 (Enterprise Value 574.6m / Total Assets 576.8m)
Interest Expense / Debt = 6.16% (Interest Expense 713k / Debt 11.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -48.2m (EBIT -61.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.67 (Total Current Assets 543.9m / Total Current Liabilities 29.1m)
Debt / Equity = 0.02 (Debt 11.6m / totalStockholderEquity, last quarter 506.1m)
Debt / EBITDA = 8.73 (negative EBITDA) (Net Debt -506.1m / EBITDA -57.9m)
Debt / FCF = 8.92 (negative FCF - burning cash) (Net Debt -506.1m / FCF TTM -56.8m)
Total Stockholder Equity = 34.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.37% (Net Income -51.9m / Total Assets 576.8m)
RoE = -24.75% (Net Income TTM -51.9m / Total Stockholder Equity 209.8m)
RoCE = -27.75% (EBIT -61.1m / Capital Employed (Equity 209.8m + L.T.Debt 10.1m))
RoIC = -8.76% (negative operating profit) (NOPAT -48.2m / Invested Capital 550.3m)
WACC = 13.43% (E(1.08b)/V(1.09b) * Re(13.52%) + D(11.6m)/V(1.09b) * Rd(6.16%) * (1-Tc(0.21)))
Discount Rate = 13.52% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -8.99 | Cagr: -8.91%
[DCF] Fair Price = unknown (Cash Flow -56.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.01 | # QB: 0
Revenue Correlation: 12.20 | Revenue CAGR: 3.50% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.45 | Chg30d=-27.63% | Revisions=+20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.47 | Chg30d=-17.50% | Revisions=+20% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.35 | Chg30d=-9.46% | Revisions=+33% | GrowthEPS=+98.3% | GrowthRev=+90.5%
EPS next Year (2027-12-31): EPS=-1.96 | Chg30d=-17.99% | Revisions=+20% | GrowthEPS=-45.4% | GrowthRev=+7.1%
[Analyst] Revisions Ratio: +33%